Latest news with #Hims&HersHealth
Yahoo
a day ago
- Business
- Yahoo
Hims & Hers Health, Inc. (HIMS) Reports Next Week: Wall Street Expects Earnings Growth
Hims & Hers Health, Inc. (HIMS) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended June 2025. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price. The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on August 4. On the other hand, if they miss, the stock may move lower. While management's discussion of business conditions on the earnings call will mostly determine the sustainability of the immediate price change and future earnings expectations, it's worth having a handicapping insight into the odds of a positive EPS surprise. Zacks Consensus Estimate This company is expected to post quarterly earnings of $0.18 per share in its upcoming report, which represents a year-over-year change of +200%. Revenues are expected to be $551.84 million, up 74.8% from the year-ago quarter. Estimate Revisions Trend The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period. Investors should keep in mind that an aggregate change may not always reflect the direction of estimate revisions by each of the covering analysts. Price, Consensus and EPS Surprise Earnings Whisper Estimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. This insight is at the core of our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction). The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier. Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only. A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP. Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell). How Have the Numbers Shaped Up for Hims & Hers Health? For Hims & Hers Health, the Most Accurate Estimate is lower than the Zacks Consensus Estimate, suggesting that analysts have recently become bearish on the company's earnings prospects. This has resulted in an Earnings ESP of -20.20%. On the other hand, the stock currently carries a Zacks Rank of #1. So, this combination makes it difficult to conclusively predict that Hims & Hers Health will beat the consensus EPS estimate. Does Earnings Surprise History Hold Any Clue? While calculating estimates for a company's future earnings, analysts often consider to what extent it has been able to match past consensus estimates. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number. For the last reported quarter, it was expected that Hims & Hers Health would post earnings of $0.12 per share when it actually produced earnings of $0.20, delivering a surprise of +66.67%. Over the last four quarters, the company has beaten consensus EPS estimates two times. Bottom Line An earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss. That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported. Hims & Hers Health doesn't appear a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release. Expected Results of an Industry Player Among the stocks in the Zacks Medical Info Systems industry, iRhythm Technologies (IRTC), is soon expected to post loss of $0.53 per share for the quarter ended June 2025. This estimate indicates a year-over-year change of +13.1%. This quarter's revenue is expected to be $173.71 million, up 17.3% from the year-ago quarter. The consensus EPS estimate for iRhythm Technologies has remained unchanged over the last 30 days. However, a lower Most Accurate Estimate has resulted in an Earnings ESP of -3%. When combined with a Zacks Rank of #3 (Hold), this Earnings ESP makes it difficult to conclusively predict that iRhythm Technologies will beat the consensus EPS estimate. Over the last four quarters, the company surpassed consensus EPS estimates two times. Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Hims & Hers Health, Inc. (HIMS) : Free Stock Analysis Report iRhythm Technologies (IRTC) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
Malaysian Reserve
2 days ago
- Business
- Malaysian Reserve
HIMS INVESTOR ALERT: Hims & Hers Health, Inc. Investors with Substantial Losses Have Opportunity to Lead Securities Class Action Lawsuit
SAN DIEGO, July 28, 2025 /PRNewswire/ — Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Hims & Hers Health, Inc. (NYSE: HIMS) securities between April 29, 2025 and June 23, 2025, all dates inclusive (the 'Class Period'), have until Monday, August 25, 2025 to seek appointment as lead plaintiff of the Hims & Hers class action lawsuit. Captioned Sookdeo v. Hims & Hers Health, Inc., No. 25-cv-05315 (N.D. Cal.), the Hims & Hers class action lawsuit charges Hims & Hers as well as certain of Hims & Hers' top executives with violations of the Securities Exchange Act of 1934. A subsequently filed complaint is captioned Yaghsizian v. Hims & Hers Health, Inc., No. 25-cv-05321 (N.D. Cal.). If you suffered substantial losses and wish to serve as lead plaintiff of the Hims & Hers class action lawsuit, please provide your information here: You can also contact attorneys J.C. Sanchez or Jennifer N. Caringal of Robbins Geller by calling 800/449-4900 or via e-mail at info@ CASE ALLEGATIONS: Hims & Hers is a telehealth company that provides prescription medications, over-the-counter medications, and personal care products. According to the complaint, on April 29, 2025, Hims & Hers announced a long-term collaboration with Novo Nordisk A/S, starting with the immediate sale of 'a bundled offering of Novo Nordisk's FDA-approved Wegovy® on the Hims & Hers platform.' The Hims & Hers class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (i) Hims & Hers was engaged in the 'deceptive promotion and selling of illegitimate, knockoff versions of Wegovy® that put patient safety at risk'; and (ii) as a result, there was a substantial risk that Hims & Hers' collaboration with Novo Nordisk would be terminated. The Hims & Hers class action lawsuit further alleges that on June 23, 2025, Novo Nordisk issued a press release announcing that it was terminating its partnership with Hims & Hers 'based on Hims & Hers deceptive promotion and selling of illegitimate, knockoff versions of Wegovy® that put patient safety at risk.' On this news, the price of Hims & Hers stock fell more than 34%, according to the complaint. THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired Hims & Hers securities during the Class Period to seek appointment as lead plaintiff in the Hims & Hers class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the Hims & Hers class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the Hims & Hers class action lawsuit. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Hims & Hers class action lawsuit. ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world's leading law firms representing investors in securities fraud and shareholder litigation. Our Firm has been ranked #1 in the ISS Securities Class Action Services rankings for four out of the last five years for securing the most monetary relief for investors. In 2024, we recovered over $2.5 billion for investors in securities-related class action cases – more than the next five law firms combined, according to ISS. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs' firms in the world, and the Firm's attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Please visit the following page for more information: Past results do not guarantee future outcomes. Services may be performed by attorneys in any of our offices. Contact: Robbins Geller Rudman & Dowd LLP J.C. Sanchez, Jennifer N. Caringal 655 W. Broadway, Suite 1900, San Diego, CA 92101 800-449-4900 info@
Yahoo
5 days ago
- Business
- Yahoo
Hims & Hers (HIMS) Soars 16% on Bullish Analyst Outlook
We recently published . Hims & Hers Health, Inc. (NYSE:HIMS) is one of the biggest performers on Wednesday. Hims & Hers rallied for a second day on Wednesday, adding 16.02 percent to close at $58.02 apiece as investors took path from an investment firm's bullish outlook and rating for the company. In a market note on Wednesday, Zacks Research gave Hims & Hers Health, Inc. (NYSE:HIMS) a 'strong buy' recommendation on expectations that its 2025 earnings per share will improve by 177.8 percent year-on-year. Zacks also underscored Hims & Hers Health, Inc.'s (NYSE:HIMS) expansion program with the recent acquisition of ZAVA, a European digital health platform operating in the UK, Germany, France, and Ireland. 'This acquisition, announced in June 2025, grants Hims & Hers access to over 1.3 million active customers and nearly 2.3 million consultations delivered in 2024 by ZAVA's in-house medical team,' Zacks noted. 'The integration of ZAVA's technology with Hims & Hers' established brand positions it to deliver personalized, seamless digital healthcare across key European markets,' it added. Pixabay/Public Domain According to Hims & Hers Health, Inc. (NYSE:HIMS), it is scheduled to announce the results of its April-June earnings performance after market close on August 4. While we acknowledge the potential of HIMS as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Upturn
20-07-2025
- Business
- Business Upturn
HIMS SECURITIES NEWS: Did Hims & Hers Health, Inc. (NYSE:HIMS) Commit Securities Fraud? Contact BFA Law by August 25 Class Action Deadline
NEW YORK, July 20, 2025 (GLOBE NEWSWIRE) — Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Hims & Hers Health, Inc. (NYSE: HIMS) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in Hims & Hers, you are encouraged to obtain additional information by visiting: Investors have until August 25, 2025, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Hims & Hers securities. The case is pending in the U.S. District Court for the Northern District of California and is captioned Sookdeo v. Hims & Hers Health, Inc., et al. , No. 25-cv-05315. A subsequent complaint alleging substantially similar claims was also filed and is captioned Yaghsizian v. Hims & Hers Health, Inc., et al. , No. 25-cv-05321. Why was Hims & Hers Sued for Securities Fraud? Hims & Hers operates a telehealth platform that provides consumers with access to online consultations with licensed healthcare professionals, prescription medications, and a range of wellness products. On April 29, 2025, Hims & Hers and Novo Nordisk announced a 'long-term collaboration' starting with the immediate sale of Novo Nordisk's popular weight loss drug Wegovy on the Hims & Hers platform. The active ingredient in Wegovy is semaglutide. As alleged, Hims & Hers touted and misrepresented to investors the nature of its partnership with Novo Nordisk, including asserting that under the terms of the agreement His & Hers could offer both Wegovy and compounded semaglutide to its customers. Hims & Hers also allegedly represented to investors that its sale of compounded semaglutide complied with FDA regulations. The Stock Declines as the Truth is Revealed On June 23, 2025, Novo Nordisk announced that it was terminating the partnership, 'based on Hims & Hers deceptive promotion and selling of illegitimate, knockoff versions of Wegovy that put patient safety at risk' and alleged that Hims & Hers 'failed to adhere to the law which prohibits mass sales of compounded drugs.' On this news, the price of Hims & Hers stock fell $22.24 per share, or more than 34%, from $64.22 per share on June 20, 2025 to $41.98 per share on June 23, 2025. Click here for more information: What Can You Do? If you invested in Hims & Hers you may have legal options and are encouraged to submit your information to the firm. All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses. Submit your information by visiting: Or contact:Ross Shikowitz [email protected] 212-789-3619
Miami Herald
19-07-2025
- Business
- Miami Herald
Popular beauty brand files for Chapter 11 bankruptcy
Beauty, skincare, and cosmetic product manufacturers have faced many of the same economic challenges that other retailers have in the last three years. Rising labor and product costs exacerbated by inflation, increased interest rates, cautious consumers who are watching their budgets in uncertain economic times, and fierce competition forced beauty brands to close and to file for bankruptcy. Don't miss the move: Subscribe to TheStreet's free daily newsletter Major cosmetics brand Avon filed for Chapter 11 bankruptcy in August 2024, two years after another huge brand, Revlon, filed for bankruptcy in June 2022. Related: National work clothing retail chain files Chapter 11 bankruptcy This year, beauty technology company Cutera filed for a prepackaged Chapter 11 bankruptcy on March 5 to reduce its debt by $400 million, and award-winning cosmetics company SBLA Beauty filed for Chapter 11 protection on March 11 to reorganize its business and restructure its debt. Telehealth company Hims & Hers Health shut down its acne treatment dermatology business, Apostrophe, on March 7 after buying the San Francisco-based company four years ago for about $190 million. Hims & Hers Health had another setback after forming a partnership with Novo Nordisk on the FDA-approved Wegovy obesity drug in April 2025. Novo Nordisk terminated the arrangement on June 23, 2025, over its concerns about Hims & Hers' "illegal mass compounding and deceptive marketing," according to a statement. Hims & Hers has not filed for bankruptcy at last check. Another skincare brand Futurewise Inc. also shut down its business as it discontinued orders on its website beginning March 24, 2025. Futurewise offered its skincare products Slug Boost, Slug Cream, Slug Balm, and Face Melt, which featured its "slugging" practice of skincare. Slugging appears to have arrived in the early 2010's with one of the first documented mentions of the term on a Reddit thread, the website said. The practice has since developed a cult-like following, Futurewise claimed. Futurewise products were also available at CVS stores, according to the skincare company's website. The skincare brand also has not filed for bankruptcy protection at last check. Popular beauty brand Essations filed for Chapter 11 bankruptcy to reorganize its business and restructure its debts on July 18. The Chicago Heights, Ill.-based personal products manufacturer and distributor, which was established in 1981, filed its petition in the U.S. Bankruptcy Court for the Northern District of Illinois, listing $100,000 to $500,000 in assets and $1 million to $10 million in debts. Related: Home Depot rival files Chapter 11 bankruptcy in distress The debtor's largest creditors include the U.S. Small Business Administration, owed $1.01 million; Nikolovski Properties, owed $115,000 in landlord claims; and the Internal Revenue Service, owed $53,000 for taxes in 2021. More bankruptcy: Major iconic food brand files for Chapter 11 bankruptcyPopular Dairy Queen rival franchisee files Chapter 11 bankruptcyPopular vision care chain files for Chapter 11 bankruptcy Other creditors include Emco Chemical Distributors, Kraft Chemicals, and Neves Global Resources. The debtor's Subchapter V petition indicated that funds would be available to distribute to unsecured creditors after administrative expenses are paid. Essation's products include a variety of haircare brands, including Essations Collection, Naked by Essations, Naked X by Essations, Textures by Naked, and Tea Tree Collection. Its haircare products include shampoos, conditioners, stylers, finishers, travel, and skin care and are available at over 170 haircare product dealers nationwide, according to its website. The company's haircare products address several hair needs, such as hair growth, volume, moisture, scalp care, hair repair, color-treated hair, frizzy hair, edges, detangling, detoxing, shine, and protein. Related: Popular pizza dining chain franchisee files Chapter 11 bankruptcy The Arena Media Brands, LLC THESTREET is a registered trademark of TheStreet, Inc.
